Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review

Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - Analyst’s summarization of the company’s business strategy.
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, that improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention; Aponvie for the prevention of postoperative nausea and vomiting (PONV) in adults; Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); and Zynrelef for the treatment of somatic postoperative pain from small to medium-sized surgical wounds in adults. Heron is headquartered in Cary, North Carolina, the US.

Heron Therapeutics Inc Key Recent Developments

• Jan 09, 2026: Heron Therapeutics Reports Preliminary Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth
• Oct 29, 2025: Heron Therapeutics Appoints Thomas Cusack to Board of Directors
• Aug 08, 2025: Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
• May 06, 2025: Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company